title: An evaluation of the polymorphisms Ins16bp and Arg72Pro in p53 as breast cancer risk modifiers in BRCA1 and BRCA2 mutation carriers.
abstract: The close functional relationship between p53 and the breast cancer susceptibility genes BRCA1 and BRCA2 has promoted the investigation of various polymorphisms in the p53 gene as possible risk modifiers in BRCA1/2 mutation carriers. Specifically, two polymorphisms in p53, c.97-147ins16bp and p.Arg72Pro have been analysed as putative breast cancer susceptibility variants, and it has been recently reported that a p53 haplotype combining the absence of the 16-bp insertion and the presence of proline at codon 72 (No Ins-72Pro) was associated with an earlier age at the onset of the first primary tumour in BRCA2 mutation carriers in the Spanish population. In this study, we have evaluated this association in a series of 2932 BRCA1/2 mutation carriers from the Consortium of Investigators of Modifiers of BRCA1 and BRCA2.
authors.affiliation: Human Cancer Genetics Programme, Human Genetics Group, Spanish National Cancer Centre, Madrid, Spain. aosorio@cnio.es
authors.forename: A
authors.initials: A
authors.lastname: Osorio
authors.forename: M
authors.initials: M
authors.lastname: Pollán
authors.forename: G
authors.initials: G
authors.lastname: Pita
authors.forename: R K
authors.initials: RK
authors.lastname: Schmutzler
authors.forename: B
authors.initials: B
authors.lastname: Versmold
authors.forename: C
authors.initials: C
authors.lastname: Engel
authors.forename: A
authors.initials: A
authors.lastname: Meindl
authors.forename: N
authors.initials: N
authors.lastname: Arnold
authors.forename: S
authors.initials: S
authors.lastname: Preisler-Adams
authors.forename: D
authors.initials: D
authors.lastname: Niederacher
authors.forename: W
authors.initials: W
authors.lastname: Hofmann
authors.forename: D
authors.initials: D
authors.lastname: Gadzicki
authors.forename: A
authors.initials: A
authors.lastname: Jakubowska
authors.forename: U
authors.initials: U
authors.lastname: Hamann
authors.forename: J
authors.initials: J
authors.lastname: Lubinski
authors.forename: A
authors.initials: A
authors.lastname: Toloczko-Grabarek
authors.forename: C
authors.initials: C
authors.lastname: Cybulski
authors.forename: T
authors.initials: T
authors.lastname: Debniak
authors.forename: G
authors.initials: G
authors.lastname: Llort
authors.forename: D
authors.initials: D
authors.lastname: Yannoukakos
authors.forename: O
authors.initials: O
authors.lastname: Díez
authors.forename: B
authors.initials: B
authors.lastname: Peissel
authors.forename: P
authors.initials: P
authors.lastname: Peterlongo
authors.forename: P
authors.initials: P
authors.lastname: Radice
authors.forename: T
authors.initials: T
authors.lastname: Heikkinen
authors.forename: H
authors.initials: H
authors.lastname: Nevanlinna
authors.forename: P L
authors.initials: PL
authors.lastname: Mai
authors.forename: J T
authors.initials: JT
authors.lastname: Loud
authors.forename: L
authors.initials: L
authors.lastname: McGuffog
authors.forename: A C
authors.initials: AC
authors.lastname: Antoniou
authors.forename: J
authors.initials: J
authors.lastname: Benitez
mesh_terms: D000328:Adult; D019313:BRCA1 Protein / Q000235:genetics*; D024682:BRCA2 Protein / Q000235:genetics*; D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology; D005260:Female; D020022:Genetic Predisposition to Disease; D005838:Genotype; D018095:Germ-Line Mutation / Q000235:genetics*; D006239:Haplotypes; D006579:Heterozygote; D006801:Humans; D010051:Ovarian Neoplasms / Q000235:genetics / Q000473:pathology; D011110:Polymorphism, Genetic / Q000235:genetics*; D012307:Risk Factors; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
chemical_list: D019313:BRCA1 Protein; D024682:BRCA2 Protein; D016159:Tumor Suppressor Protein p53
references.citation: Nat Genet. 2001 Dec;29(4):418-25
references.pmid: 11694875
references.citation: BMC Cancer. 2008 Jan 29;8:32
references.pmid: 18230179
references.citation: Hum Hered. 2004;57(4):200-6
references.pmid: 15583426
references.citation: Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12111-6
references.pmid: 17626182
references.citation: Cancer Detect Prev. 2006;30(6):523-9
references.pmid: 17113725
references.citation: Int J Cancer. 2003 Jan 20;103(3):431-3
references.pmid: 12471629
references.citation: Breast Cancer Res. 2007;9(2):R27
references.pmid: 17428325
references.citation: Breast Cancer Res. 2007;9(2):104
references.pmid: 17466083
references.citation: Lung Cancer. 2002 Mar;35(3):231-5
references.pmid: 11844595
references.citation: J Natl Cancer Inst. 2002 May 1;94(9):681-90
references.pmid: 11983757
references.citation: Hum Mutat. 2006 Mar;27(3):242-8
references.pmid: 16419081
references.citation: Genet Epidemiol. 2005 Jul;29(1):1-11
references.pmid: 15880399
references.citation: Nat Genet. 2003 Mar;33(3):357-65
references.pmid: 12567188
references.citation: J Med Genet. 2003 Apr;40(4):e34
references.pmid: 12676907
references.citation: Oncogene. 2003 Jun 12;22(24):3749-58
references.pmid: 12802282
references.citation: Cancer Epidemiol Biomarkers Prev. 1997 Feb;6(2):105-12
references.pmid: 9037561
references.citation: Anticancer Res. 1998 May-Jun;18(3B):2095-9
references.pmid: 9677474